# A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

> **NCT05160168** · PHASE1,PHASE2 · TERMINATED · sponsor: **Theseus Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors (GIST)
- Neoplasms, Connective Tissue
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasm
- Digestive System Disease
- Gastrointestinal Diseases

## Interventions

- **DRUG:** THE-630

## Key facts

- **NCT ID:** NCT05160168
- **Lead sponsor:** Theseus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-03
- **Primary completion:** 2024-02-02
- **Final completion:** 2024-02-02
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** The Sponsor terminated the study due to early dose-limiting toxicities.
- **Last updated:** 2024-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05160168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05160168, "A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05160168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*